Effect of complete decongestive therapy and home program on health- related quality of life in post mastectomy lymphedema patients

Table 4 Test of between subjects effects for all measures

	Groups	Mean(range) (95 % CI)	Mean differences (95 % CI)	F
VAS	CDT	3.81 (3.53–4.10)	0.98 (0.58–1.38)	23.82*
VAS	CT	4.79 (4.51–5.07)	0.98 (0.58–1.38)	23.82*
EORTC QLQ C30 Global scale	CDT	43.54 (41.88–45.21)	2.97 (0.61–5.32)	6.36*
EORTC QLQ C30 Global scale	CT	40.58 (38.91–42.24)	2.97 (0.61–5.32)	6.36*
EORTC QLQ C30 Functional scale	CDT	82.82 (82.26–83.38)	1.94 (1.15–2.74)	24.06*
EORTC QLQ C30 Functional scale	CT	80.89 (80.32–81.44)	1.94 (1.15–2.74)	24.06*
EORTC QLQ C30 Symptoms scale	CDT	44.02 (42.81–45.24)	2.10 (0.38–3.82)	6.01*
EORTC QLQ C30 Symptoms scale	CT	41.92 (40.71–43.14)	2.10 (0.38–3.82)	6.01*
EORTC QLQ BR23 Functional scale	CDT	35.57 (34.76–36.37)	2.38 (1.24–3.52)	17.47*
EORTC QLQ BR23 Functional scale	CT	33.19 (32.38–33.99)	2.38 (1.24–3.52)	17.47*
EORTC QLQ BR23 Symptoms scale	CDT	61.18 (60.14–62.22)	1.52 (0.05–2.10)	4.28*
EORTC QLQ BR23 Symptoms scale	CT	59.66 (58.61–60.70)	1.52 (0.05–2.10)	4.28*

CT conventional therapy, CDT complete decongestive therapy, VAS visual analogue scale, *Statistically significant (p < 0.05)

ISSN: 1472-6874